Search
Viking Therapeutics Inc
VKTXAdd to Watchlist
27.280USD
+0.420+1.56%
Close 10-30 16:00（ET）
3.47BMarket Cap
LossP/E TTM
After-hours 17:40 (ET)27.070USD-0.245-0.90%
After-hours 17:40 (ET)Viking Therapeutics Inc (VKTX) Stock Price Target & Forecast
Analyst Rating
Based on 20 analysts giving stock ratings to Viking Therapeutics Inc in the past month.
Buy
7 Strong Buy
11 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
97.000USD+282.49%
VKTX Analyst Recommendation Trends
In the current month, VKTX has received 11 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. VKTX average Analyst price target in the last month is 97.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
7
7
7
7
7
7
7
7
11
11
11
11
11
10
10
10
2
2
2
2
2
2
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
20
20
20
19
19
18
VKTX Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Biontech SE
BNTX
4
11
8
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Cytokinetics Inc
CYTK
5
15
2
0
0
22
Financial Forecasting
Based on analysts' estimates, VKTX EPS is projected to reach -1.289 in FY2026Q4, following reported EPS of -1.552 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-1.01
-1.25
-1.07
-1.29
-1.23
Actual
-1.37
-1.10
-1.55
--
--
Surprise
-35.11%
+11.70%
-45.65%
--
--
FAQs
What is Viking Therapeutics Inc's price target?
Analysts forecast that Viking Therapeutics Inc's price target is USD 97.00, with the highest forecast at USD 125.00 and the lowest forecast at USD 34.00.
How have Viking Therapeutics IncVKTX's recent earnings per share performed?
The market expectation was USD -1.55, while Viking Therapeutics IncVKTX's earnings per share (EPS) for the previous quarter was USD -1.10. EPS for the next quarter is expected at USD -1.29.
What is the analyst rating for Viking Therapeutics Inc?
Based on the ratings of Viking Therapeutics Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.